{
    "address": "Rorstrandsgatan 58",
    "city": "Stockholm",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W4863R103",
    "description": "ISR Immune System Regulation Holding AB engages in pharmaceutical research for the treatment of viral diseases focusing on Human Immunodeficiency Virus (HIV). The company is headquartered in Stockholm, Stockholm. The company went IPO on 2017-03-24. The firm is focused the development of drug therapies for viral infections, in particular human immunodeficiency virus (HIV). The firm's product candidate, ISR048, is undergoing phase II of clinical trials for HIV indications. The company provides a resistance profile, which does not require co-dosing with a boosting agent. A second generation anti-HIV drug candidate, ISR049, is in preclinical development. The firm's another drug candidate in development, ISR050, shows immunostimulatory properties that are being explored in vitro and in animal models of chronic infections, such as tuberculosis.",
    "employeeTotal": "",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2017-03-24",
    "isin": "SE0008212195",
    "logo": "https://finnhub.io/api/logo?symbol=ISR.ST",
    "marketCapitalization": 235.1345,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "ISR Immune System Regulation Holding AB (publ)",
    "phone": "46705427939.0",
    "sedol": "BYZBVD5",
    "shareOutstanding": 53.131416,
    "state": "STOCKHOLM",
    "ticker": "ISR.ST",
    "weburl": "http://israb.se"
}